REG - ValiRx PLC - Cytolytix Patent Granted

ValiRxAnnouncement

27/05/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260527:nRSa7799Fa&default-theme=true

RNS Number : 7799F  ValiRx PLC  27 May 2026

27 May 2026

 

ValiRx PLC

("ValiRx" or the "Company")

 

Cytolytix Patent Granted

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health is pleased to provide the
following updates on its majority owned subsidiary Cytolytix Limited
("Cytolytix").

Cytolytix's European Patent application "Nanoparticle for Anti-Cancer Peptides
and Uses Thereof" (application No. 21798092.9) has been granted in Europe with
the publication number EP4225803B1. This patent, licensed from King's College
London, forms a key part of the Cytolytix intellectual property portfolio.

 

The grant of this first European patent strengthens Cytolytix's intellectual
property position and the directors believe affirms the investment in the
innovative platform ValiRx has developed over the last few years. The granted
intellectual property strengthens the Company's ability to attract external
investment as well as increasing the Company's offerings for licensing and
partnership opportunities.

 

ValiRx expects to be able to provide further updates on the core European
Patent Application "Polyleucine-Based Peptides As Anti-Cancer Agents"
(application No. 20793085.0). As announced on 1 September 2025, the Company
has requested accelerated examination following the filing of routine
amendments to the patent description.

 

Whilst these two patent families represent core IP for Cytolytix, the Company
filed additional patent protection on 26 May 2026 for new inventions relating
to its second-generation delivery platform based on novel liposomal
formulations of the oncolytic peptide.

 

The new patent application includes data demonstrating induction of
immunogenic cell death in Triple Negative Breast Cancer Cells, a key component
of the mechanism of action that could provide enhanced and more durable
responses when translated to the clinical setting.

 

ValiRx CEO and Cytolytix Director, Mark Eccleston, will be presenting
Cytolytix's oncolytic peptide program at the Oxford Global Discovery and
development conference in Berlin (14-16 June 2026) following a series of
presentations earlier in the year. ValiRx is continuing its discussions with
several potential partners to progress Cytolytix, including a major
pharmaceutical company and further non-dilutive funding options.

 

Mark Eccleston, CEO of ValiRx commented "We are delighted to see the grant of
one Cytolytix's core patents by the European Patent Office, confirming that
the platform is both novel and inventive, and I am equally delighted that we
have now filed on our own proprietary position in the oncolytic peptide space.
We will continue to expand these core patents with new IP developed using in
house expertise at ValiRx and Inaphaea and we expect to further strengthen our
portfolio with new filings in H2. The filing of the new patent also allows us
to talk freely about this approach with potential partners providing a
platformtowards commercialisation.

 

"The new patent is built on data developed with the combined experience and
resources of our tCRO, Inaphaea Biolabs, with the advanced nonanimal
3D-culture testing capabilities in triple negative breast cancer models on
Screenin3D's UpScale(3D)lab-on-a-chip platform, one of our key capability
partners. Further in-vivo zebrafish data was generated with another capability
partner, Bioreparia.

 

"The potential immune boost feature of this class of therapeutics could
significantly enhance both efficacy and durability of response and we are
moving forward with VoxCell's proprietary, fully perfusable vascularised 3D
tissue culture models to validate recruitment of the host immune system as we
announced in July 2025.

 

"In addition to its application in human Triple Negetive Breast Cancer, our
oncolytic peptide program will form a key part of our Animal Health
subsidiary, and we will be providing further updates on this in due course."

 

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.

Cautionary statement

 

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

 

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 

 Investor questions on this announcement           https://valirx.com/link/PQRDGy

 We encourage all investors to share questions

 on this announcement via our investor hub
 ValiRx plc                                        Tel: +44 115 784 0026

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                    +44 (0) 115 646 5491

                                                   www.vformation..co.uk

 Jocelyn Braithwaite

                                                   jocelyn@vformation.co.uk

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFLIEVIRFIR



            Copyright 2019 Regulatory News Service, all rights reserved